Concordia Healthcare Corp. T.CXR.R

please check date on top...its sep 6

[fundtrader]

September 6, 2016 Concordia International Corp. Script Tracker - Week Ended August 26th Our view: We continue to highlight Rx trends in our CXRX notes, and consequently we believe it is important to provide investors with a more in-depth view of script trends. As previously noted, a generic version of Nilandron was approved on July 18. Key points: Plaquenil AG TRx flat WoW, in-line with broader market. Plaquenil AG (Prasco) TRx were flat WoW vs. down 2.1% the prior week. Total hydroxychloroquine (broader plaquenil market) TRx were up 0.5% WoW and Prasco's market share (Concordia AG) currently sits at 38.1% of TRx vs. 38.3% the prior week. We have outlined Plaquenil/ hydroxychloroquine market share trends in Exhibit 2. As previously noted, we believe Plaquenil AG pricing has decreased by ~40% recently and we note that Concordia confirmed that Plaquenil AG is seeing further pricing pressure. We had previously noted that we believed this pricing pressure was due to the entry of NorthStar's generic in Q2/16, but can now confirm that it is due to Actavis's generic (1.9% market share).
Lanoxin AG TRx up 0.9% WoW. Par's (AG) market share increased from 29.9% to 30.3%, Sun Pharma's market share was flat WoW at 11.2%, WestWard Pharma's share increased from 9.3% to 9.5%, Digoxin saw its share decrease from 25.4% to 25.1%, and Impax's share decreased from 23.0% to 22.8%. The Lanoxin AG (Par Pharma) saw TRx increase 0.9% WoW vs. a 1.9% decrease last week. The broader market saw TRx decrease 0.4% WoW. We have outlined Lanoxin/Digoxin market trends in Exhibit 3.
Donnatal TRx up 10.8% WoW. As previously noted, we have been monitoring the market share of several IBS drugs that target both IBSC and IBS-D, and we anticipate that Donnatal scripts have seen slight weakness in the face of Allergan’s Viberzi launch (TRx up 3.3% WoW), which came to market in December 2015. Donnatal NRx were up 12.1% WoW vs. down 3.4% the prior week and TRx were up 10.8% WoW vs. down 2.7% the prior week. Donnatal's current market share (TRx) is 1.8%; Xifaxan holds a 16.2% market share, Viberzi has a 3.9% share, Amitiza has a 27.0% share, and Linzess has a 50.8% share. Exhibit 5 shows Donnatal weekly NRx and TRx trends.
Other CXRX products: Nilandron TRx up 17.1% WoW, Dibenzyline AG TRx down 59% WoW, and Kapvay TRx down 16.0% WoW. Nilandron saw TRx of 41, up 17.1% WoW. We note that ANI Pharmaceuticals had a generic version of Nilandron approved by the FDA on July 18 and saw TRx increase 5.6% WoW to 19. We anticipate that CXRX will launch an AG in the coming weeks.

[dannyd9]

Thanks fundtrader; i did not know that rbc did a week over week comparison of scripts. I think in this case it was important because the bottom is falling out of the stock and douglas miehm wanted to show that the business is not.  The stock has seen a relentless selling indicative of something worse than what we know. If the quarter comes in at estimates without further downward revisions

[fundtrader]

NP Danny..Cant go wrong buying at 8 $ .IF MT is fired and we get update on Strategic Review this will double from here ...I just picked up more at 10.20..today...

[Shane007]

fundtrader:  YOU SAID WE COULDN'T GO WRONG ON JULY 27th WHEN IT WAS $24.65 LIAR. quote=fundtrader]NP Danny..Cant go wrong buying at 8 $ .IF MT is fired and we get update on Strategic Review this will double from here ...I just picked up more at 10.20..today... [/quote]

[Craigbad]

I truly feel bad for you. I just hope your young, can recover at some point from this and you don't have much invested here. Alot of people have been duped and still are. 

[fundtrader]

Craig thanks for your concern but lets talk in a few months shall we..i am expecting huge returns from my investment here..

[Marky1]

Funtrader..I too expect a healthy return on my stock here...I've averaged down to 11.88$ cdn...Am expecting some good news from management soon....Good luck,!

[Craigbad]

Are you and your friends still emailing the company everyday to ask them to release positive news to make the shareprice go up? Maybe you should start emailng twice a day to give them more encouragement?

[LaticelnExile]

This post has been removed in accordance with Community Policy

[PROtrading]

OMG, ladies and gentlement, please don't follow traders who are looking for others to buy these shares heading for the rocks in the Caymen Islands (along with that insider's 1.6M shares!)! Buying as a stock retests its lows will only work if oversold conditions get corrected but they won't. The stock and company would have to be clean. Look at TA: THERE IS NO SUPPORT!!!  We have

[Craigbad]

Here is the report you may be looking for from Rbc. The biggest standout for me (and the market obviously) was the recent price decrease of 40% of Plaquenil. Ouch! 

[greatplay]

Nope; not this one; this one is about decrease of existing, which is no surprise, that's why share is not $100+; Report was about projection annual projection ($); in addition it was talking about future new drugs for 2017 and 2018; I googled it, even I thought, I posted it, but can't find anywhere; It wasn't by a bull, but rather "hold" company

[Craigbad]

It may be for another application of Photofrin. They're try to get another indication for bile duct cancer i believe. If they do get it approved it will be a long road to revenue because normal headwinds and you would have to buy an expensive laser to even treat one patient. Its a photodynamic treatment so its not just a matter of pushing pills through the system and will likely require